Webcast - Managing Rashes Associated with Anti-HCV Triple Therapy

When a new educational resource is released online this blog provides readers with background information and links to the new activity.

Last month over at Projects In Knowledge three new learning activities were launched all discussing HCV triple therapy.

The first update includes two new chapters added to the sites "HCV Care and Guidance e-handbook," also called "The Living Medical eTextbook."

Chapter 10 and 11 updates:
Chapter 10 offers current data on efficacy, safety and response to first-generation protease inhibitors in HCV patients with compensated cirrhosis; Hepatitis C Treating Hepatitis C in Patients with Cirrhosis  and chapter 11 highlights important recent data and label updates for boceprevir and telaprevir; Anti-Hepatitis C Triple Therapy Update

*Additional chapters are provided below.

Webcast - Managing Rashes Associated with Anti-HCV Triple Therapy

A new webcast hosted by Anne Croghan, ARNP, will discuss dermatologic adverse events associated with HCV triple therapy.

Hepatitis C — Managing Rashes Associated with Anti-HCV Triple Therapy
By: Anne Croghan, ARNP

Dermatologic adverse events related to anti-HCV triple therapy are a challenge for both clinicians and patients. Boceprevir and telaprevir each have had recent label changes related to dermatologic events. Join Anne Croghan, ARNP, for this webcast in which she discusses rash assessment, symptom control, medication management, monitoring and referral, and patient education. “Managing Rashes Associated with Anti-HCV Triple Therapy,” is part of the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program. 

Free Registration
As with any CME free registration is required. Once this is accomplished participants taking part in the webcast can skip the pre-test and go directly to the webcast by clicking on the "Activity Button."

May 29, 2013 two new e-handbook chapters offered
Practical Education and Resources

NEW Chapter 10 Hepatitis C - Treating Hepatitis C in Patients with Cirrhosis
By: P. Horne, BSN, MSN

Boceprevir and telaprevir triple therapies offer an improved opportunity for sustained virologic response (SVR) in patients with HCV-related compensated cirrhosis. SVR rates are significantly higher compared with traditional combination therapy in treatment-naive as well as treatment–experienced patients, ... Boceprevir and telaprevir triple therapies offer an improved opportunity for sustained virologic response (SVR) in patients with HCV-related compensated cirrhosis. SVR rates are significantly higher compared with traditional combination therapy in treatment-naive as well as treatment–experienced patients, particularly those who were prior relapsers. In this e-handbook chapter, Patrick M. Horne, BSN, MSN, reviews the importance of diagnosing cirrhosis prior to starting anti-HCV therapy and highlights efficacy and safety data, as well as on-treatment monitoring tips. “Treating Hepatitis C in Patients with Cirrhosis,” is part of the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.  

NEW Chapter 11  Anti-Hepatitis C Triple Therapy Update
By: Sherilyn C. Brinkley, MSN, CRNP

Since the approval of boceprevir and telaprevir triple therapy in 2011, studies in real-life clinical settings as well as retrospective reviews of phase III data have been undertaken to better understand how to optimize success with these first-generation protease inhibitors. Join Sherilyn C. Brinkley, MSN, CRNP, for this e-handbook chapter, in which she highlights important recent data and label updates for boceprevir and telaprevir triple therapy. “Anti-Hepatitis C Triple Therapy Update,” is part of the HCV Care and Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants program.  

Other topics offered in the e-handbook
Chapter 1 Getting Ready for Direct-Acting Antiviral (DAA) Therapy
Chapter 2 What You Need to Know About the New Direct-Acting Antiviral (DAA) Regimens Chapter 3 Hematologic Adverse Effects
Chapter 4 Dermatologic Adverse Effects
Chapter 5 Gastrointestinal Adverse Effects
Chapter 6 Neuropsychiatric Adverse Effects
Chapter 7 Understanding Drug-Drug Interactions in this New Triple-Therapy Era
Chapter 8 Treating HCV in Special Populations
Chapter 9 Predictors of Response
Chapter 10 Treating Hepatitis C in Patients with Cirrhosis
Chapter 11 Anti-Hepatitis C Triple Therapy Update

Related
Video- Hepatologist Urges caution among clinicians in the administration of telaprevir
High Incidence of Telaprevir-associated Severe Rash Leading to Discontinuation
HCV  Drug Incivek (telaprevir) - View Rash  Grade 1 and  2